Inflammatix
Inflammatix builds host-response diagnostics that rapidly assess acute infection and sepsis in emergency care.
Founded
2016Inflammatix builds host-response diagnostics that rapidly assess acute infection and sepsis in emergency care.
The TriVerity test measures host-response mRNA rather than pathogen genetic material, so it can read immune signatures in whole blood even when infections remain locally contained. Its accuracy was validated in the SEPSIS-SHIELD study across 1,222 patients at 22 sites.
The system is engineered for bedside deployment near the patient, with an under-a-minute hands-on workflow, room-temperature cartridge storage, no regular maintenance, roughly 11.5 inches of bench space, and multiple LIS connectivity options. FDA Breakthrough Device designation and January 2025 clearance anchor its regulatory standing.
Source: inflammatix.com
Inflammatix sells a cleared rapid host-response diagnostic for emergency departments, where faster infection and severity reads can change antibiotic and admission decisions. TriVerity's January 2025 FDA clearance, Breakthrough Device designation, and SEPSIS-SHIELD validation across 1,222 patients at 22 sites give it a defined regulatory and evidence base.
The business pairs a compact Myrna instrument with single-use cartridges suited to near-patient workflows, and its Stanford-licensed biomarker engine supports a pipeline spanning emerging infections, autoimmune disease, and transplant rejection. That combination of a cleared flagship and a broad host-response platform frames the company's growth case.
Source:
The flagship offering is the TriVerity Test System, a rapid blood test that measures 29 host-response genes in whole blood and applies machine-learning classifiers to deliver three scores: likelihood of bacterial infection, likelihood of viral infection, and illness severity within seven days. It runs on the Myrna instrument, a compact point-of-care platform designed for routine emergency department workflows.
Results arrive in roughly 30 minutes, supporting earlier decisions on antibiotics, additional testing, and admission or discharge in suspected acute infection or sepsis. Accuracy was validated in the SEPSIS-SHIELD study across 1,222 patients at 22 sites.
Source: inflammatix.com